Sino Biopharm and its subsidiaries form a leading innovation and R&D-driven pharmaceutical group in China, with a business that covers the entire industry chain, including a pharmaceutical R&D platform, intelligent manufacturing, and a robust sales system. Its products include a variety of biologics and chemical drugs, holding a leading position in four major therapeutic fields: Oncology, Hepatology, Respiratory, and Surgery/Analgesic.

The company was listed on the Hong Kong Stock Exchange in 2000，the stock symbol is 01177. In 2013, it was included as a component of the MSCI Global Standard Index in China. In 2018, it became a constituent stock of the Hang Seng Index. In 2019, it was added to the Hang Seng China Enterprises Index. In 2020, it was included in the HSSCB50 Index and the Hang Seng China (Hong Kong-listed) 25 Index. Sino Biopharm has been ranked among the "Top 50 Global Pharmaceutical Enterprises" published by the authoritative U.S. magazine Pharm Exec for seven consecutive years, with its latest global ranking at 39th and 2nd in China. It has also been rated as the "Top 50 Best Companies in Asia" by Forbes (Asia) for three consecutive years.

Sino Biopharm has subsidiaries located in Beijing, Shanghai, Nanjing, Lianyungang, etc., with multiple drug production bases. Since its establishment, the company has consistently achieved outstanding results and steady growth. Its core enterprises, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. and Beijing Tide Pharmaceutical Co., Ltd., have been ranked among the Top 100 Pharmaceutical Companies in China for many years.

Sino Biopharm will uphold its mission of "Science for a healthier world", and strive to be a leading global pharmaceutical company through delivering innovative therapies for patients. We look forward to sharing the development achievements of the pharmaceutical and healthcare industry with partners from all sectors, and working together for a win-win future!